QA-68

QA-68

• UNSPSC Description: QA-68 (QA-68-ZU81) is an effective PROTAC-class BRD9 degrader. QA-68 can inhibit cell cycle progression and cell colony formation. QA-68 has antiproliferative activity against acute myeloid leukemia (AML) cell lines[1]. QA-68 can be formed by a target protein ligand (red part) EA-89 (HY-170314), an E3 ubiquitin ligase ligand (blue part) Lenalidomide-I (HY-131318), and a PROTAC linker (black part) Ethyne-C2-Pip-CO-Pip-Boc (HY-170315). E3 ubiquitin ligase and linker can form Lenalidomide-ethyne-C2-Pip-CO-Pip (HY-170319).
• Target Antigen: Epigenetic Reader Domain; PROTACs
• Type: Reference compound
• Related Pathways: Epigenetics;PROTAC
• Applications: COVID-19-immunoregulation
• Field of Research: Cancer; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/qa-68.html
• Solubility: 10 mM in DMSO
• Smiles: CCCN1C=C(C2=C(C1=O)C=C(C(NC3CCS(CC3)(=O)=O)=O)S2)C4=CC=C(C5=C4)N(C=C5C)CC6CCN(CC6)C(CCC(N7CCN(CC7)C(N8CCN(CC8)CCC#CC9=CC=CC%10=C9CN(C%10=O)C%11CCC(NC%11=O)=O)=O)=O)=O
• Molecular Weight: 1169.42
• References & Citations: [1]Weisberg E, et al. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. Blood Cancer J. 2022 Jul 19;12(7):110.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported